3/18
01:11 am
halo
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]
3/13
11:32 pm
halo
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]
Low
Report
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]
3/12
08:54 am
halo
Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]
Medium
Report
Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]
3/12
08:30 am
halo
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
Medium
Report
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
3/11
01:23 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
3/10
03:08 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/10
07:28 am
halo
Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science [Yahoo! Finance]
Low
Report
Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science [Yahoo! Finance]
3/6
08:19 am
halo
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
Low
Report
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
3/6
08:00 am
halo
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Low
Report
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
3/4
07:03 pm
halo
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns [Yahoo! Finance]
3/4
06:31 pm
halo
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback [Yahoo! Finance]
Medium
Report
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback [Yahoo! Finance]
3/3
08:57 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/1
04:40 am
halo
Is Halozyme Therapeutics (HALO) a Buy Post Earnings? [Yahoo! Finance]
Low
Report
Is Halozyme Therapeutics (HALO) a Buy Post Earnings? [Yahoo! Finance]
2/28
12:10 pm
halo
Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory [Yahoo! Finance]
Low
Report
Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory [Yahoo! Finance]
2/26
06:07 am
halo
Halozyme Therapeutics (HALO) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c)".
Low
Report
Halozyme Therapeutics (HALO) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c)".
2/25
08:56 am
halo
Halozyme to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Halozyme to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/25
08:47 am
halo
2 Reasons to Like HALO (and 1 Not So Much) [Yahoo! Finance]
Low
Report
2 Reasons to Like HALO (and 1 Not So Much) [Yahoo! Finance]
2/25
08:30 am
halo
Halozyme to Participate in Upcoming Investor Conferences
Low
Report
Halozyme to Participate in Upcoming Investor Conferences
2/19
07:05 pm
halo
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation [Yahoo! Finance]
Low
Report
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation [Yahoo! Finance]
2/19
02:28 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Benchmark Co. from $75.00 to $90.00. They now have a "buy" rating on the stock.
2/19
09:44 am
halo
Halozyme (HALO) Loses 9% on Weak Earnings [Yahoo! Finance]
Low
Report
Halozyme (HALO) Loses 9% on Weak Earnings [Yahoo! Finance]
2/19
09:34 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Wells Fargo & Company from $65.00 to $75.00. They now have an "equal weight" rating on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at Wells Fargo & Company from $65.00 to $75.00. They now have an "equal weight" rating on the stock.
2/18
12:05 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/18
12:12 am
halo
Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/17
08:29 pm
halo
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript [Seeking Alpha]